Method for synthesizing mono pegylation-thymopentin by solid phase and liquid phase combination

A technology of PEGylation and solid-phase synthesis, which is applied in chemical instruments and methods, carrier binding/immobilization of peptides, peptides, etc., to achieve the effect of accurate structure, good mass production basis, and mature synthesis route.

Active Publication Date: 2010-10-27
LANZHOU UNIVERSITY
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, TP5 can only be administered by frequent injection or intravenous infusion, which brings great pain and mental stress to the patient.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for synthesizing mono pegylation-thymopentin by solid phase and liquid phase combination
  • Method for synthesizing mono pegylation-thymopentin by solid phase and liquid phase combination
  • Method for synthesizing mono pegylation-thymopentin by solid phase and liquid phase combination

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0022] A method for synthesizing PEGylated Thymopentin with a solid-liquid phase method, the steps of which are divided into:

[0023] a. The monomethoxypolyethylene glycol modification (mPEG-SCM) was connected to the side chain amino group of α-amino-protected lysine (ε-NH 2 ); 400mg of fluorenylmethoxycarbonyl-protected lysine hydrochloride (Fmoc-lys-OH.HCl) reacted with 700mg of monomethoxypolyethylene glycol modification (mPEG-SCM), and the reaction system was 6ml of chloroform and 24ml of dioxane; 800 μl of diisopropylethylamine (N, N-Diisopropylsilane, referred to as DIEA) was added dropwise at room temperature to keep the pH at 9.0, stirred by magnetic force, and reacted overnight; Add 40mL of water to dissolve, filter out water-insoluble matter, dialyze with a dialysis bag (MW, 3500) for 48 hours, and freeze-dry to obtain 600mg of white powder (Fmoc-lys(PEG)-OH), with a yield of 78.5%.

[0024] The NMR data of the product are as follows:

[0025] 1 H-NMR (DMSO) 7.31...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a method for synthesizing mono pegylation-thymopentin (mPEG-TP5) by solid phase and liquid phase combination. The method comprises the following steps of: connecting modified polyethylene glycol (mPEG-SCM) to side chain amino of lysine protected by amino by adopting liquid-phase synthesis technology; synthesizing mPEG-TP5 by adopting solid-phase synthesis technology; analyzing and purifying high-efficiency liquid phase through dialysis; and identifying the product structure through nuclear magnetism and mass spectrum. The mono pegylation-thymopentin synthesized by themethod improves the defect that the conventional parent medicament thymopentin has quick biodegradation, poor digesting stability, short biological half-life and the like, and has good application prospect.

Description

technical field [0001] The invention relates to the synthesis of PEGylated Thymopentin by adopting a liquid-phase and solid-phase synthesis technique. Background technique [0002] Thymopentin (Thymopentin, TP5) is a synthetic small molecule peptide consisting of 5 amino acid residues, which has the same biological activity as endogenous thymopoietin II in regulating the immune balance of the body. For a variety of immune dysfunction or hypofunction, TP5 can make the immune function tend to normal through the two-way regulation of promotion or inhibition. At present, it has been widely used clinically, and can be used for the treatment of: (1) malignant tumor; (2) chronic hepatitis; (3) surgery and severe infection; (4) diabetes; (5) autoimmune disease; (6) menopause syndrome; (7) aging and frailty, etc. However, TP5 is quickly degraded by protease and aminopeptidase after injection into the human body, and the half-life of the drug prototype is only 30 seconds. However, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K17/08
Inventor 倪京满王锐王长林李倩
Owner LANZHOU UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products